Android app on Google Play

Sarepta Therapeutics (SRPT) Riding High On Successful Drug

August 30, 2012 8:08 AM EDT Send to a Friend
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive, tear-jerking press.

Yesterday evening, KFVS Jakson, MO highlighted the case of 12 year old Justin Trovillion. Since he enter the trial for Sarepta's Eteplirsen "Justin has a new energy for life," his mother said. "He is able to do so much more."

Sarepta has seen massive press after one of two Vermont brothers - Austin And Max Leclaire - saw similarly positive results while the other struggled.

Shares of Sarepta, which are up over 200 percent in the last three months, is up another 5 percent in pre-open trading to a new 52-week high of $13.25.




You May Also Be Interested In


Related Categories

FDA, Momentum Movers, Trader Talk

Related Entities

Twitter

Add Your Comment